NEXT PHASE

By Lucy Parkinson, VP of Investor Research, LSN

RESI Healthtech Week, a three-day event starting September 5^th, will offer an expanded agenda of panels and workshops for entrepreneurs looking for advice on how to raise capital (grants, seed, angels, series A and series B rounds) for their ventures.

At the First Coast Innovator’s Gathering (RESI Healthtech Week Day 1 on September 5th), the focus will be on the very earliest stages of fundraising and entrepreneurship. Attendees can catch panels on Seed Funds, Angels, Foundations, the NIH, and Big Pharma at the Seed Stage, as well as a workshop on raising nondilutive grant funding. The goal is to set up the earliest stage companies for success by providing additional information on funding they have not previously received. Additionally, the agenda includes the First Coast Innovation Challenge, a competition for the First Coast Innovators to pitch their company to selected investors in the afternoon.

On Day 2 (September 6th), the RESI Global Partnering event will focus on panels about global early stage investments (series A and series B) in life science companies from RESI’s core verticals of therapeutics, medical devices, diagnostics and digital health. The agenda includes new sessions on Impact Investors, and Investing in Personalized Medicine, as well as two sessions focused on investors from the Asia-Pacific region – Investors Leveraging the CFDA and Asia Cross-Border Investors. Also featured are many more topical sessions on the newest trends in life science investment.

The Entrepreneur’s Academy Workshop Series on Day 3 (September 7th) features a full day of entrepreneurship workshops for attendees to learn how to brand and market their company to investors, create an investor target list, and send outbound marketing within an organized campaign to raise capital. We hope you can join us for this exciting new three-day event.

By Jessica Yang, Investor Research Analyst, LSN

On June 4^th, more than 700 scientist-entrepreneurs and investors entered the exhibition hall at Boston Marriott Copley Place to participate in the RESI conference. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and digital health sectors. The 30 companies, evaluated by LSN’s expert system and scientific & commercial review team, competed directly on merits of innovation and commercial viability. We wish all our finalists the best in bringing their products forward toward commercialization, but there could only be 3 top prize winners.

First Prize: Taiwan Resonant Waves Research Corp.

Taiwan Resonant Waves Research Corp. (TRWR) was founded in 2010 in the capital of Taiwan – Taipei. Integrating innovative bioelectronic technology with non-invasive medical devices, we are dedicated to helping patients with chronic diseases better manage health-related challenges.There is unlimited promise in the application of Bioelectrical medicine in the treatment of chronic diseases. Designed and developed by TRWR, Microcurrent Electrical Nerve Stimulation technology (MENS) is currently being used as a non-invasive, physical approach to treating and alleviating symptoms associated with diabetes (such as decreasing HbA1c of Type 2 Diabetes Mellitus patient). Our vision is to lead the world in groundbreaking research and development in electroceutical technology as a means of enhancing quality of life, without the adverse side effects of conventional approaches.

Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN | Chris Chen, Business Development, TRWR | Ann Chiu, COO, TRWR | Kuo-Chuan Huang, Doctor, TRWR

Second Prize: The Wave Talk

Our laser-based sensor is many times more accurate than conventional laser and is able to detect even low concentrations of bacteria based on its movements in real-time. Even though our first application targets water, we have managed to decrease antibiotics susceptibility test from 10-15 hours to less than 1 hour.

Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN | SeungA LEE, Marketing, UX, The Wave Talk | YoungDug Kim, CEO & Founder, The Wave Talk

Third Prize: Taipeibio

Taipeibio is an R&D-driven company with core technology derived from Harvard and MIT; which focuses on tissue regeneration and repairs various bone defects including alveolar bone, bone, joint, ligament and cartilage. Taipeibio has comprehensive global IP protection in over 45 countries (Fish & Richardson; Cesari & McKenna). Taipeibio has established 3 core labs and 5 research arms to support product development with 2 governmental funding programs . Taipeibio has accumulated over 160 successful clinical cases with 14 years stress-bearing data to prove safety and efficacy. The cartilage regeneration product has been proved to repair large articular cartilages and difficult TMJ defects in a rabbit model. Relative scientific reports were published in high-impact SCI journals. The products will be made in U.S.A. and aiming FDA approval.

Natasha Eldridge, Director of RESI Conference Series, LSN | Lucy Parkinson, Director of Investor Research, LSN | Dr. Thomas Wen-Fu Lai, TaipeiBio | Jim-Pei Chu, CEO, TaipeiBio

It is worth mentioning that the proportion of Asia-based startups at RESI is the highest it’s ever been. LSN worked closely with both Development Center of Biotechnology (DCB) from Taiwan and Korea Trade-Investment Promotion Agency (KOTRA).  Of the over 100 startups that applied to be finalists in the RESI Innovation Challenge, more than 30% were from Taiwan or Korea.  This is also the first time that Asia-based companies won all three top prizes. The first and third place winners were two Medtech companies from Taiwan, Taiwan Resonant Waves Research Corp and TaipeiBio respectively. The second place winner was THE WAVE TALK, one of the Korea-based companies sponsored by KOTRA. Check out how RESI collaborates with KOTRA.

By Nono Hu, Director of Marketing, LSN

In 4 days, The Redefining Early Stage Investments (RESI) Conference will kick off a bustling week for the global healthtech industry in Boston. At RESI Boston, over 300 investors will be under one roof in search of compelling connections with early stage companies.

Check out the program guide now to plan for a productive day at RESI packed with partnering meetings, innovative technologies, and up-to-date investment knowhow.

See you at RESI on June 4th at the Boston Marriott Copley Place!

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series & First Coast Healthtech Week

The inaugural First Coast Healthtech Week (FCHW) launches on September 5th at the Boston Marriott Copley Place with a new conference – the Healthcare Innovators Gathering, where incubators, accelerators, tech transfer, university translation initiatives, hospitals, research labs and their constituents from DC, MD, PA, NJ, NY, RI, CT and MA (the first coast) will gather for the first time in one location to get on the radar screens of potential global partners. The Healthcare Innovators Gathering is followed by the RESI Global Partnering Conference, September 6th, and the Entrepreneurs Academy Workshop Series, September 7th.

LSN’s established network of early stage global investors attend RESI Conference Series to source, engage and allocate funds to startup firms across the silos of biotech, medtech, diagnostics, and digital health. In addition, we present the First Coast Healthtech Week!

“The First Coast is blessed with an amazing amount of technological assets addressing unmet medical needs across the entire healthcare spectrum. They need to get in front of global investors,” says Dennis Ford, CEO at Life Science Nation. This includes over 100 incubators, accelerators, tech transfer, university translation initiatives, hospitals, and research labs each with aggregate portfolios of 1000 or more assets.

Chuck Stetson, CEO of Stetson Family Office, is a Title Sponsor of the Healthtech Innovators Investor Summit on September 5th, and the RESI Global Investor Conference on September 6th. Stetson is pioneering a new, nonprofit, evergreen, endowment model for early stage global companies within technology rich innovation hubs. “It is time to address the developmental ‘valley of death’ and muster state-of-the-art resources to bring breakthrough technologies to market faster,” Stetson stated.

LSN invites the technology hubs, and their scientist/entrepreneurs, of the First Coast to take advantage of this inaugural launch. LSN created an affordable registration price that will facilitate more startups attending the three-day event. “We had to get the price point right as the early stage folks have been priced out of most of the other conferences,” said Ford. Register for the event at www.firstcoasthealthtech.com.

Qualifying First Coast day 1 registrants are the north east corridor incubators, accelerators, tech transfer, university translation initiatives, hospitals, research labs and their constituents as well as the investors and partners that seek them. Day 2 and 3 are open to all global attendees – scientist entrepreneurs, fundraising CEOs, investors, channel partners and service providers.

By Christine A. Wu, Senior Research Analyst, LSN

While mental and behavioral health conditions are highly prevalent, they are also often stigmatized. In the healthcare technology arena, this indication area has been on the rise in both excitement and innovation. According to the World Health Organization, one out of four people in the world suffer from a mental or neurological disorder, including a total of about 450 million people with mental disorders. Even as one of the leading causes of ill-health and disability worldwide, mental illness carries with it stigma, discrimination, and neglect, preventing patients from admitting the need for help, reaching for help or having the accessibility to resources for when they do. In a society that shies away from vulnerability, it becomes easy for us to not embrace the need for mental health or fully understand how to prevent future cases.

Industry and investors have responded; with the growth of the digital health vertical, the amount of capital invested in the mental and behavioral healthcare space has increased significantly. This year, the industry has seen deals as high as $40M in digital health platforms streamlining patients and mental health clinicians, mobile apps with professional coaching, and software solutions to overcome anywhere from anxiety and depression to eating disorders and substance abuse. As chronic diseases such as diabetes and inflammatory bowel disease can be debilitating for patients both medically and psychologically, behavioral health solutions include disease management IT platforms to monitor and improve treatment adherence. With the aim to treat individuals holistically, such platforms connect patients, mental health professionals, and medical physicians, tracking the patient’s physical and mental health as the disease progresses.

At RESI Boston Summer on Monday, June 4th, the LSN team is launching an initiative to highlight investment in mental and behavioral health with a new expert panel of VCs, pharma, hospital and healthcare systems.

Moderated by Julie Papanek Grant, Partner at Canaan Partners, the panel includes:

• Justin Baker, Scientific Director, The McLean Institute for Technology in Psychiatry
• Ken Duckworth, Senior Medical Director for Behavioral Health, Blue Cross Blue Shield of MA
• Robert Garber, Partner, 7wire Ventures
• Eric Schaeffer, Senior Director, Neuroscience Innovation, Johnson & Johnson Innovation

Panelists will provide their diverse perspectives of industry (and academia) trends in mental and behavioral health, its future outlook, and global impact.

The LSN team has also slated a handful of digital health companies in mental and behavioral health for the RESI Innovation Challenge.

Register for RESI and be sure to meet and learn both the investor side and company side of this up-and-coming space!

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) is launching a new early stage global investor conference called First Coast Healthtech Week, September 5-7^th in Boston, MA. The goal is to improve access to the earliest stage companies within the healthcare industry across the First Coast: DC, MD, PA, NJ, NY, RI, CT, and MA essentially the North East Corridor. Life Science Nation wants to expand access to early stage global investors and partners to the earliest stage technology and innovation hubs.

By James Huang, Research Analyst, LSN

We are excited to showcase the top RESI Innovation Challenge startup applicants, who will be taking part in the poster presentation showcase at the second annual RESI BIO held in Boston this year, alongside the BIO International conference. These handpicked companies represent the key sectors of the healthcare space including therapeutics, medical devices, diagnostics and digital health, and were selected based on their scientific/technical merit and commercial viability. Additionally, this Innovation Challenge will feature select companies from Korea and Taiwan to showcase innovation that is also occurring overseas.

The Innovation Challenge companies will compete for each attendee’s RESI Cash tokens throughout the day, which serves as a vote of their potential. The top 3 companies will win additional RESI tickets to events of their choosing and a feature in the LSN newsletter (20,000 readership), giving them access to hundreds of additional investors and ultimately enhancing their likelihood of securing an investment. Make sure to visit the exhibition hall to meet the RESI innovators and “invest” in your favorites!

Biotech

Diagnostic

MedTech Device

Digital Health